| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/24/2005 | WO2005026193A2 Small molecules and a pharmacophore model for inhibition of botulinum toxin and methods of making and using thereof |
| 03/24/2005 | WO2005026185A1 Novel indolopyrrolocarbazole derivative with antitumor activity |
| 03/24/2005 | WO2005026184A2 Synthesis and compositions of 2'-terminator nucleotides |
| 03/24/2005 | WO2005026177A1 Substituted piperazines of azepines, oxazepines, and thiazepines |
| 03/24/2005 | WO2005026173A1 Substituted thienoimidazoles, method for production and use thereof as medicament or diagnostic and medicaments comprising the same |
| 03/24/2005 | WO2005026171A1 Substance which exhibits antiviral and antibacterial activity and is based on derivatives of 2,8-dithioxo-1h-pyrano[2,3d¸6,5-d']dipyrimidyne and 10-aza-analogue thereof |
| 03/24/2005 | WO2005026167A1 Process for preparing famciclovir |
| 03/24/2005 | WO2005026165A1 Quinolone antibacterial agents |
| 03/24/2005 | WO2005026164A1 Pharmacologically active imidazo[4,5-c]pyridines |
| 03/24/2005 | WO2005026161A1 Antibacterial agents |
| 03/24/2005 | WO2005026159A1 Benzoxazole acetonitriles |
| 03/24/2005 | WO2005026158A1 2,4 di (hetero) -arylamino-pyrimidine derivatives as zap-70 and/or syk inhibitors |
| 03/24/2005 | WO2005026156A1 Quinazoline derivatives |
| 03/24/2005 | WO2005026154A1 Quinolone antibacterial agents |
| 03/24/2005 | WO2005026153A1 Quinazoline-2, 4-diones as antibacterial agents |
| 03/24/2005 | WO2005026152A1 Quinazoline derivatives as antitumor agents |
| 03/24/2005 | WO2005026151A1 Quinazoline derivatives as tyrosine kinase inhibitors |
| 03/24/2005 | WO2005026147A1 7-(4-substituted 3- cyclopropylaminomethyl-1 pyrrolidinyl) quinolonecarboxylic acid derivative |
| 03/24/2005 | WO2005026146A1 Azetidinyl quinolones as antibacterial agents |
| 03/24/2005 | WO2005026140A1 Process for the preparation of crystalline forms of orlistat |
| 03/24/2005 | WO2005026138A1 2-naphthylimino-1,3-thiazine derivative |
| 03/24/2005 | WO2005026137A2 Modulators of atp-binding cassette transporters |
| 03/24/2005 | WO2005026133A1 Isoxazoles as peptide deformylase inhibitors |
| 03/24/2005 | WO2005026132A1 cAMP-SPECIFIC PHOSPHODIESTERASE INHIBITOR |
| 03/24/2005 | WO2005026131A1 Transition state structure and inhibitors of thymidine phosphorylases |
| 03/24/2005 | WO2005026130A1 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders |
| 03/24/2005 | WO2005026128A1 Ophthalmic compositions for treating ocular hypertension |
| 03/24/2005 | WO2005026120A1 Matrix metalloproteinase inhibitors |
| 03/24/2005 | WO2005026117A1 Preventive for cerebral stroke recurrence |
| 03/24/2005 | WO2005026114A1 Hiv protease inhibitors, compositions containing the same and their pharmaceutical uses |
| 03/24/2005 | WO2005026112A2 Methods of treating a disorder |
| 03/24/2005 | WO2005026111A2 Heteroaromatic selective inhibitors of neuronal nitric oxide synthase |
| 03/24/2005 | WO2005026109A1 Cyclopentane heptan(ene)oic acid, 2-thiocarbamoyloxy and carbamoyloxy compounds as therapeutic agents |
| 03/24/2005 | WO2005026106A1 Process of hydrocyanation of unsaturated carboxylic acid derivatives |
| 03/24/2005 | WO2005026083A2 Improved delivery by labile hydrophobic modification of drugs |
| 03/24/2005 | WO2005026048A1 Porous silica having substance carried thereon |
| 03/24/2005 | WO2005025675A1 Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors |
| 03/24/2005 | WO2005025674A1 Combination of phenylcarboxamides with beta-adrenergic receptor blockers and use thereof for the treatment of atrial arrhythmias |
| 03/24/2005 | WO2005025673A1 Multi-system therapy for diabetes, the metabolic syndrome and obesity comprising a hypoglycemic agent |
| 03/24/2005 | WO2005025629A1 Cyanoacrylate monomer formulation containing diiodomethyl-p-tolylsulfone |
| 03/24/2005 | WO2005025622A1 Bitterness-masking particulate jelly beverage |
| 03/24/2005 | WO2005025621A1 Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness |
| 03/24/2005 | WO2005025620A2 Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents |
| 03/24/2005 | WO2005025619A1 Combination of a histone deacetylase inhibitor with a death receptor ligand |
| 03/24/2005 | WO2005025589A1 Composition and method for facilitating bone healing |
| 03/24/2005 | WO2005025587A1 Composition comprising ginkgolides and bilobalide |
| 03/24/2005 | WO2005025586A1 Cytokine modulators and related method of use |
| 03/24/2005 | WO2005025583A2 Tlr7 ligands for the treatment of hepatitis c |
| 03/24/2005 | WO2005025582A1 Antibacterial compositions of n-acetyl-d-aminoglycosamine and antibiotics |
| 03/24/2005 | WO2005025581A1 Use of n-acetyl-d-aminoglycosamine in preparation of drugs for the treatment of cacer and metastasis |
| 03/24/2005 | WO2005025580A1 Use of n-acetyl-d-aminoglycosamine in preparation of drugs for modulating microorganisms on mucous membrane |
| 03/24/2005 | WO2005025579A1 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators |
| 03/24/2005 | WO2005025578A1 Use of ciclesonide for the treatment of respiratory diseases |
| 03/24/2005 | WO2005025577A1 Use of ciclesonide for the treatment of inflammatory bowel diseases |
| 03/24/2005 | WO2005025575A1 Protective solution used during eye treatments |
| 03/24/2005 | WO2005025574A2 PTERIDINE DERIVATIVES FOR THE TREATMENT OF SEPTIC SHOCK AND TNF-α-RELATED DISEASES. |
| 03/24/2005 | WO2005025573A1 Compositions and methods for treating pain |
| 03/24/2005 | WO2005025572A1 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators |
| 03/24/2005 | WO2005025571A1 A pharmaceutical composition comprising a p2x7 receptor antagonist and a nonsteroidal anti inflammatory drug. |
| 03/24/2005 | WO2005025570A1 Use of antagonists of hepatic sympathetic nerve activity |
| 03/24/2005 | WO2005025569A1 Use of known active ingredients as radical scavengers |
| 03/24/2005 | WO2005025568A1 Ophthalmic compositions for treating ocular hypertension |
| 03/24/2005 | WO2005025567A1 Benzothiazole derivatives for the treatment of diabetes |
| 03/24/2005 | WO2005025565A1 Microbicide composition comprising a minor groove binder optionally in combination with an anti-hiv compound and use thereof in the prevention of sexually transmitted diseases |
| 03/24/2005 | WO2005025564A1 Oral pharmaceutical formulations of rofecoxib |
| 03/24/2005 | WO2005025563A1 Combination comprising an alpha-2-delta ligand and an ssri and/or snri for treatment of depression and anxiety disorders |
| 03/24/2005 | WO2005025562A1 Treating and/or preventing urinary incontinence using prodrugs of gaba analogs |
| 03/24/2005 | WO2005025561A1 Compositions and methods for orthostatic intolerance |
| 03/24/2005 | WO2005025560A1 Ophthalmic composition |
| 03/24/2005 | WO2005025559A1 Treatment of gastroparesis and nonulcer dyspepsia with gabab agonists |
| 03/24/2005 | WO2005025558A1 Sulfonamide derivatives for the treatment of diabetes |
| 03/24/2005 | WO2005025557A1 An agent for plasminogen-activation and matrix metalloproteinase associated conditions and methods of use |
| 03/24/2005 | WO2005025556A2 Antibiotic cycloalkyltetrahydroquinoline derivatives |
| 03/24/2005 | WO2005025555A2 Combinations of an aryl aniline beta-2 adrenergic receptor agonist and a corticosteroid |
| 03/24/2005 | WO2005025554A2 Dipeptidyl peptidase iv inhibitor |
| 03/24/2005 | WO2005025553A2 Treatment of disorders of nervous systemsystem with fty720 |
| 03/24/2005 | WO2005025552A2 Protein binding compounds |
| 03/24/2005 | WO2005025551A2 Pharmaceutical products comprising bisphosphonates |
| 03/24/2005 | WO2005025550A1 Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation |
| 03/24/2005 | WO2005025549A2 Multi-layer transdermal drug delivery device |
| 03/24/2005 | WO2005025546A1 Agent containing ergolin for transdermal application |
| 03/24/2005 | WO2005025542A1 Fine grain having fat-soluble drug encapsulated therein, process for producing the same and preparation containing the same |
| 03/24/2005 | WO2005025541A2 Dry powder composition comprising a benzodiazepine for pulmonary inhalation |
| 03/24/2005 | WO2005025540A2 Mucoactive agents for treating a pulmonary disease |
| 03/24/2005 | WO2005025539A1 Ophthalmic composition for contact lens |
| 03/24/2005 | WO2005025538A1 Composition for medical use containing sugar chain-containing chitosan derivative and glycosaminoglycan |
| 03/24/2005 | WO2005025536A2 Dry powder composition comprising co-jet milled particles for pulmonary inhalation |
| 03/24/2005 | WO2005025535A2 Methods for preparing pharmaceutical compositions |
| 03/24/2005 | WO2005025520A2 Chitosan spinning method, device therefor, and resulting chitosan yarn, and uses thereof |
| 03/24/2005 | WO2005025517A2 Animal model for protease activity and liver damage |
| 03/24/2005 | WO2005025515A2 Proteasome pathway inhibitors and related methods |
| 03/24/2005 | WO2005025513A2 Guanidinium derivatives for improved cellular transport |
| 03/24/2005 | WO2005025512A2 Cobalamin conjugates for anti-tumor therapy |
| 03/24/2005 | WO2005025511A2 Potassium channel mediated delivery of agents through the blood-brain barrier |
| 03/24/2005 | WO2005025510A2 Cox-2 selective inhibitor with extended duration |
| 03/24/2005 | WO2005025507A2 Dihydropyridine compounds for treating or preventing metabolic disorders |
| 03/24/2005 | WO2005025504A2 Modulators of calcitonin and amylin activity |
| 03/24/2005 | WO2005025501A2 Co-administration of polysaccharide with a chemotherapeutic agent for the treatment of cancer |
| 03/24/2005 | WO2005025500A2 Process for preparing water soluble diterpenes and their applications |
| 03/24/2005 | WO2005025499A2 Hydrophobic drug compositions containing reconstitution enhancer |